Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand

Verrica Pharmaceuticals

11/03/2026 12:10

Overview

Dermatology therapeutics firm's Q4 adjusted loss per share beat analyst expectations

Q4 revenue rose sharply yr/yr, driven by higher YCANTH demand and license revenue

Company repaid all outstanding debt and extended cash runway into Q1 2027

Outlook

Company expects to initiate second Phase 3 study of YCANTH in US and Japan in mid-2026

Verrica says cash runway extends into first quarter of 2027

Company preparing pivotal Phase 3 studies of VP-315 for basal cell carcinoma in 2026

Result Drivers

YCANTH DEMAND - Higher product revenue in Q4 was driven by increased demand for YCANTH, as reflected in the rise in dispensed applicator units

LICENSE REVENUE - License and collaboration revenue increased, primarily from commercial supply for YCANTH's launch in Japan

LOWER OPERATING COSTS - Selling, general and administrative expenses fell due to reduced commercial activities and a smaller sales force

Company press release: ID:nGNX9Ms64S

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
-$0.51
-$0.79 (3 Analysts)
Q4 Adjusted Net Income
-$7.20 mln
Q4 Net Income
-$8.07 mln
Q4 Income from Operations
-$7.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $18.00, about 201% above its March 10 closing price of $5.98

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)